REG - IXICO plc - Operational Update

IXICOAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA3535Ja&default-theme=true

RNS Number : 3535J  IXICO plc  01 December 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

IXICO strengthens Scientific Advisory Board with two prominent global
Alzheimer's Disease and vascular experts

 

-Appointments announced at 2025 CTAD Conference form part of a concerted
dementia research and product innovation strategy, particularly in the area of
vascular biomarkers  -

 

01 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader
in neuroscience imaging and biomarker analytics, using its AI-driven platform
to help advance drug development in neurological disorders, today announced
that it has appointed two leading global experts in the field of Alzheimer's
Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company.
Professor  Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory
board with immediate effect.

 

The announcement is being made as part of IXICO's participation in the 18th
CTAD conference (Clinical Trials on Alzheimer's Disease) which starts today.
CTAD is an annual cornerstone event in Alzheimer's Diseases (AD) clinical
research, where IXICO will be presenting research on its capabilities for the
accurate assessment of positron emission tomography (PET) imaging in clinical
trials.

 

Professor Micheal Weiner, MD.

Michael is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine,
Psychiatry, and Neurology at the University of California, San Francisco. He
is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative
(ADNI), which is the largest observational study in the world concerning
Alzheimer's Disease. Michael's full biography is available in the notes at the
bottom of this announcement.

 

Professor Joanna Wardlaw, MD, CBE.

Joanna is a is Professor of Applied Neuroimaging at the University of
Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row
Fogo Centre for research into Ageing and the Brain, and Consultant
Neuroradiologist for NHS Lothian. Joanna's full biography is available in the
notes at the bottom of this announcement.

 

IXICO Vascular Biomarker Innovation

The appointments support IXICO's strategy to deepen its presence in
Alzheimer's Disease and develop a series of biomarker algorithms to identify
and measure vascular abnormalities which are a common contributing factor in
neurodegenerative disease where MRI can provide an established biomarker for
vascular abnormalities. While particularly relevant for screening, safety and
efficacy in AD, measuring vascular components and abnormalities has wider
applications in other neurological therapeutic areas such as Cerebral Amyloid
Angiopathy (CAA), Stroke, and Multiple Sclerosis.  The first in a series of
planned vascular biomarker algorithms is already being made available to IXICO
clients on their clinical trials with further releases planned for the current
financial year.

 

Robin Wolz, Chief Scientific Officer of IXICO, commented: "It is exciting to
be working with Professor Weiner and Professor Wardlaw reflecting IXICO's
commitment to advancing the understanding of the interplay between Alzheimer's
disease and cerebrovascular pathology. Collaborating with distinguished
experts in the field directly supports our work to develop and validate
vascular biomarker algorithms that address a critical gap in current AD
trials.

 

By enabling more precise screening, a better understanding of the multiple
factors and causes involved in disease, and providing sensitive measures of
vascular burden throughout the trial, these biomarkers have the potential to
significantly improve trial design and the interpretability of efficacy
results. These appointments mark an important step in IXICO's strategy to
broaden our biomarker innovation portfolio and deepen our engagement in
Alzheimer's disease."

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

About Michael Weiner, MD

Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical
Imaging, Medicine, Psychiatry, and Neurology at the University of California,
San Francisco. He is Principal Investigator of the Alzheimer's Disease
Neuroimaging Initiative, which is the largest observational study in the world
concerning Alzheimer's Disease. He is the former Director of the Center for
Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans
Affairs Medical Center. His overall research goals are to participate in the
development of effective treatments and methods for early detection of
Alzheimer's disease and other brain disorders. Recently he has focused on
developing voice agents for assessments in AD clinical trials.

 

Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging
Initiative, a 19-year national longitudinal study of over 3,500 subjects which
is aimed at validating biomarkers for Alzheimer's disease at 63 sites across
the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He
also launched the BrainHealthRegistry.org which is an internet-based registry
with the overall goal of accelerating development of effective treatments for
brain diseases. This website registry recruits, screens, and longitudinally
monitors brain function on more than 100,000 participants.

 

Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000
peer reviewed research papers and 71 book chapters. He has received numerous
honors including the Young Investigator Award of the American College of
Cardiology in 1976, and more recently, the Nancy and Ronald Regan Award from
the Alzheimer's Association, the Potamkin Prize of the American Academy of
Neurology, a Docteur Honoris Causa Degree from Paul Sabatier University,
Toulouse, France in 2019, and the Henry Wisniewski Lifetime Achievement Award
in Alzheimer's Disease Research, from the Alzheimer's Association in 2021.

 

 

About Professor Joanna Wardlaw, CBE, MB ChB (Hons), MD, FRCR, FRCP, FMedSci,
FRSE

Joanna is a is Professor of Applied Neuroimaging at the University of
Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row
Fogo Centre for research into Ageing and the Brain, and Consultant
Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain
and its blood supply, and treatments to improve blood flow to the brain,
including thrombolytic drugs that are now in routine use to treat stroke, and
more recently treatments for small vessel disease and vascular dementia.
Working with many colleagues, she has been instrumental in advancing
understanding of the causes of cerebral small vessel disease and is now
testing treatments in clinical trials.

 

She has set up national research imaging facilities, co-ordinated
international research networks, advanced stroke care worldwide and published
over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK
Academy of Medical Sciences, she has received awards from many UK and
international brain and heart organisations and was made a Commander of the
Order of the British Empire (CBE) for services to Medicine and Neuroscience in
2016.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPGPCGUPAGMM



            Copyright 2019 Regulatory News Service, all rights reserved